As part of our growth strategy, we are looking for sustainable, long-term acquisitions. We are interested in acquisitions within our current therapeutic areas; bolt-on acquisitions in neighboring pharmaceutical areas are equally interesting.
Our acquisition criteria
- Pharmaceuticals backed by studies or patents
- Targets with an annual turnover of up to 250 million euros
- Collaborations and start-ups are also of interest
- Focus regions in Western Europe as well as North and South America
